CompletedNot Applicable

Assessment of Maternal and Fetal Serum Biomarkers in Women With Pre-eclampsia

Iraq204 participantsStarted 2024-12-13

Plain-language summary

The findings of markers of placental dysfunction in women with preeclampsia may suggest that these biomarkers may be useful tools for early detection of preeclampsia

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age group 18-45 years * Gestational age of 26-41 weeks at the time of diagnosis for preeclampsia * Delivered vaginally or abdominally * Being of any parity (para 1 and more) * Pregnancy being singleton or multiple pregnancies * Willingness to provide informed consent Exclusion Criteria: * Pregnant woman having chronic hypertension * Having Diabetes mellitus * The lady on medications that can affect inflammatory markers or blood pressure * Pregnant with fetal anomalies * Refused to involve in the research

What they're measuring

To compare the levels of maternal and fetal serum soluble Fms-like tyrosine kinase-1 (sFlt-1), seromucoid, and protein-bound hexose between women with pre-eclampsia and a control group of healthy pregnant women.

Timeframe: one hour

Trial details

NCT IDNCT06712550

SponsorSHAHLA KAREEM ALALAF

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-03

View on ClinicalTrials.gov More Inflammatory Markers trials